Frequency of adverse clinical events in the 12 months following successful intracoronary stent placement in patients treated with aspirin and ticlopidine (without warfarin).

[1]  L. Schwartz,et al.  Intracoronary-stent placement for coronary artery disease , 1997, The Lancet.

[2]  M. Hadamitzky,et al.  Major benefit from antiplatelet therapy for patients at high risk for adverse cardiac events after coronary Palmaz-Schatz stent placement: analysis of a prospective risk stratification protocol in the Intracoronary Stenting and Antithrombotic Regimen (ISAR) trial. , 1997, Circulation.

[3]  C. Di Mario,et al.  Intracoronary stent implantation in native coronary arteries and saphenous vein grafts: a consecutive experience with six types of stents without prolonged anticoagulation. , 1997, Mayo Clinic proceedings.

[4]  W. Baxley,et al.  Utilization of the coronary balloon-expandable coil stent without anticoagulation or intravascular ultrasound. , 1996, Circulation.

[5]  M. Hadamitzky,et al.  A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. , 1996, The New England journal of medicine.

[6]  W Rutsch,et al.  Heparin-coated Palmaz-Schatz stents in human coronary arteries. Early outcome of the Benestent-II Pilot Study. , 1996, Circulation.

[7]  A. Colombo,et al.  A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. , 1996, Circulation.

[8]  H. Krumholz,et al.  In-hospital and one-year economic outcomes after coronary stenting or balloon angioplasty. Results from a randomized clinical trial. Stent Restenosis Study Investigators. , 1995, Circulation.

[9]  P Hall,et al.  Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. , 1995, Circulation.

[10]  D. Faxon.  Effect of high dose angiotensin-converting enzyme inhibition on restenosis: Final results of the MARCATOR study, a multicenter, double-blind, placebo-controlled trial of cilazapril , 1995 .

[11]  S. Goldberg,et al.  Benefit of intracoronary ultrasound in the deployment of Palmaz-Schatz stents. , 1994, Journal of the American College of Cardiology.

[12]  W Rutsch,et al.  A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. , 1994, The New England journal of medicine.

[13]  S. Goldberg,et al.  Intracoronary ultrasound observations during stent implantation. , 1994, Circulation.

[14]  R. Califf,et al.  A Comparison of Directional Atherectomy with Coronary Angioplasty in Patients with Coronary Artery Disease , 1993 .

[15]  F. Loop,et al.  Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty). , 1988, Circulation.

[16]  T. Ryan.  Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty). , 1988, Journal of the American College of Cardiology.

[17]  P. Teirstein,et al.  A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. , 1994, The New England journal of medicine.

[18]  U. Deligonul.  Coronary Morphologic andClinical Determinants ofProcedural OutcomeWith Angioplasty forMultivessel Coronary Disease Implications forPatient Selection , 1990 .